1. Home
  2. TCRX

TCRX

TScan Therapeutics Inc.

Logo TScan Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Founded: 2018 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 368.4M IPO Year: 2021
Target Price: $11.00 AVG Volume (30 days): 164.6K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.36 EPS Growth: N/A
52 Week Low/High: $1.62 - $9.00 Next Earning Date: 05-08-2024
Revenue: $21,049,000 Revenue Growth: 55.52%
Revenue Growth (this year): -19.98% Revenue Growth (next year): -31.14%

Share on Social Networks: